Savara (SVRA) Change in Account Payables (2016 - 2017)

Savara (SVRA) reported Change in Account Payables of -$127000.0 for Q1 2017, up 83.63% year-over-year from -$69159.3 in Q1 2016, and up 83.63% on a QoQ basis from -$776000.0 in Q1 2016.

Savara (SVRA) has 2 years of Change in Account Payables data on file, last reported at -$127000.0 in Q1 2017.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Account Payables (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -3.26 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 35.60 Mn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 Savara 1.30 Bn 1.30 Bn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2017 -127,000.00
Mar 31, 2017 -127,000.00
Mar 31, 2016 -776,000.00
Mar 31, 2016 -776,000.00